Scynexis (SCYX) Preferred Stock Liabilities (2013 - 2014)
Scynexis (SCYX) posted Preferred Stock Liabilities of $4.2 million for Q1 2014, down 82.52% on a QoQ basis from $24.1 million in Q4 2013.
Scynexis (SCYX) Preferred Stock Liabilities (2013 - 2014) Analysis & Trends
Scynexis' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $4.2 million for Q1 2014.
- Quarterly Preferred Stock Liabilities changed N/A year-over-year to $4.2 million in Q1 2014, while the trailing twelve-month figure through Mar 2014 was $4.2 million (changed N/A YoY) and the FY2013 annual result came in at $24.1 million, changed N/A from the prior year.
- Preferred Stock Liabilities was $4.2 million for Q1 2014 at Scynexis, down from $24.1 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $24.1 million in Q4 2013 and bottomed at $4.2 million in Q1 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Scynexis | 21.55 Mn | -15.20 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2014 | 4.22 Mn |
| Dec 31, 2013 | 24.12 Mn |